Pomalidomide

Thalidomide Analog — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Pomalidomide is an ofp drug in the Thalidomide Analog class catalogued in DrugCentral. It was first approved by the FDA in 2013. DrugCentral lists 4 molecular targets, including TNF, IL1B and CRBN. Recorded indications include Multiple myeloma.

• Approval status: ofp (first approved 2013 by the FDA).
• Drug class: Thalidomide Analog.
• Molecular targets: TNF, IL1B, CRBN and Cereblon isoform 4 (4 listed in DrugCentral).
• Indications: Multiple myeloma.
• ATC code: L04AX06 (Other immunosuppressants).
• Molecular formula: C13H11N3O4; molecular weight 273.25 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Multiple myeloma

Mechanism & targets

• Established pharmacologic class: Thalidomide Analog

Molecular targets (4)

Target	Gene	Action	Activity
Tumor necrosis factor	TNF	unknown	IC50 7.48
Interleukin-1 beta	IL1B	unknown	IC50 7.33
Protein cereblon	CRBN	modulator	EC50 6.58
Cereblon isoform 4	—	unknown	Ki 6.10

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2015-03-26	PMDA	—	CELGENE K.K.	Yes
2013-02-08	FDA	—	CELGENE	Yes

ATC classification

ATC code	Therapeutic hierarchy
L04AX06	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Other immunosuppressants

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Death	6671.8
Pneumonia	3775.1
White blood cell count decreased	3474.0
Full blood count decreased	3017.7
Neutropenia	2979.8
Neuropathy peripheral	2318.3
Laboratory test abnormal	1711.5
Fatigue	1675.6
Plasma cell myeloma recurrent	1006.5
Thrombosis	964.7
Neutrophil count decreased	947.5
Platelet count decreased	934.1

Chemical structure

• Molecular formula: C₁₃H₁₁N₃O₄
• Molecular weight: 273.25 g/mol
• CAS number: —
• InChIKey: UVSMNLNDYGZFPF-UHFFFAOYSA-N
• PubChem CID: 134780

NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Pomalidomide used for?

DrugCentral lists the following indications for Pomalidomide: Multiple myeloma.

How does Pomalidomide work?

Its molecular targets in DrugCentral include TNF, IL1B, CRBN (modulator) and Cereblon isoform 4.

When was Pomalidomide first approved?

Pomalidomide was first approved by the FDA in 2013.

What drug class does Pomalidomide belong to?

Pomalidomide is in the Thalidomide Analog class.

What is the chemical formula of Pomalidomide?

Pomalidomide has the molecular formula C13H11N3O4 and a molecular weight of 273.25 g/mol.

Sources

• DrugCentral drug card 4746 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL43452 — compound record and bioactivity
• PubChem CID 134780 — chemical identifiers
• DrugBank DB08910 — drug record
• FDA UNII D2UX06XLB5 — substance identity
• DailyMed: FDA labels for Pomalidomide — current prescribing information (label search)
• UniProt P01375 (TNF) — target protein
• UniProt P01584 (IL1B) — target protein
• UniProt Q96SW2 (CRBN) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.